Switch theme
Sign up to access all valuation multiples
JFL Life Sciences Ltd is engaged in the business of manufacturing pharmaceutical products. The company's product portfolio consists of Dry powder injections (B-Lactam), Tablets and Capsules (B-Lactam) solid oral dosage forms, and general tablets and capsules. Its operating segment comprises of manufacturing and selling of pharmaceutical products. Geographically, the company sells its products both in India and outside India.
2010
39
Last FY Revenue $5.5M
Last FY EBITDA $0.6M
$8.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, JFL Life Sciences achieved revenue of $5.5M and an EBITDA of $0.6M.
JFL Life Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See JFL Life Sciences valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $5.5M | XXX | XXX | XXX |
| Gross Profit | XXX | $0.9M | XXX | XXX | XXX |
| Gross Margin | XXX | 17% | XXX | XXX | XXX |
| EBITDA | XXX | $0.6M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 11% | XXX | XXX | XXX |
| EBIT | XXX | $0.5M | XXX | XXX | XXX |
| EBIT Margin | XXX | 9% | XXX | XXX | XXX |
| Net Profit | XXX | $0.4M | XXX | XXX | XXX |
| Net Margin | XXX | 7% | XXX | XXX | XXX |
| Net Debt | XXX | $0.7M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, JFL Life Sciences's stock price is INR 19 (or $0).
JFL Life Sciences has current market cap of INR 630M (or $7.4M), and EV of INR 687M (or $8.0M).
See JFL Life Sciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8.0M | $7.4M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, JFL Life Sciences has market cap of $7.4M and EV of $8.0M.
JFL Life Sciences's trades at 1.5x EV/Revenue multiple, and 13.8x EV/EBITDA.
Equity research analysts estimate JFL Life Sciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
JFL Life Sciences's P/E ratio is not available.
See valuation multiples for JFL Life Sciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7.4M | XXX | $7.4M | XXX | XXX | XXX |
| EV (current) | $8.0M | XXX | $8.0M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 1.5x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 13.8x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 16.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 19.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 30.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialJFL Life Sciences's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $11K for the same period.
JFL Life Sciences's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
JFL Life Sciences's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for JFL Life Sciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 11% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $11K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
JFL Life Sciences acquired XXX companies to date.
Last acquisition by JFL Life Sciences was XXXXXXXX, XXXXX XXXXX XXXXXX . JFL Life Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was JFL Life Sciences founded? | JFL Life Sciences was founded in 2010. |
| Where is JFL Life Sciences headquartered? | JFL Life Sciences is headquartered in India. |
| How many employees does JFL Life Sciences have? | As of today, JFL Life Sciences has 39 employees. |
| Is JFL Life Sciences publicy listed? | Yes, JFL Life Sciences is a public company listed on NSE. |
| What is the stock symbol of JFL Life Sciences? | JFL Life Sciences trades under JFLLIFE ticker. |
| When did JFL Life Sciences go public? | JFL Life Sciences went public in 2022. |
| Who are competitors of JFL Life Sciences? | Similar companies to JFL Life Sciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of JFL Life Sciences? | JFL Life Sciences's current market cap is $7.4M |
| Is JFL Life Sciences profitable? | Yes, JFL Life Sciences is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
